JointHealth™ express   December 14, 2010

Cimzia and Simponi now covered under Ontario's Exceptional Access Program

Good news for those living with arthritis in Ontario – as of October 28, certolizumab pegol (Cimzia®) and golimumab (Simponi®) are listed for coverage under Ontario's Exceptional Access Program (EAP). Now there are more treatment options available in Ontario, which is important because every patient responds differently to disease suppressing or modifying medications.

Certolizumab pegol (Cimzia®) is a medication used to treat rheumatoid arthritis. It is an anti-TNF medication taken by subcutaneous injection every two weeks (200mg/mL pre-filled syringe). Golimumab (Simponi®) is used to treat rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It is taken by subcutaneous injection every four weeks (50mg/0.5mL pre-filled syringe and auto-injector).

Click here to view the most up-to-date version of ACE's Report Card on provincial formulary reimbursement listings for biologic response modifiers.

These two drugs have been approved for reimbursement under the Ontario Public Drug Program's EAP program, according to specific clinical criteria, as laid out in the document entitled, "Reimbursement Criteria for Frequently Requested Drugs and Indications"

The Exceptional Access Program facilitates patient access in exceptional circumstances to drugs not funded on the Ontario Drug Benefit (ODB) Formulary, or where no listed alternative is available